Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics.
10.3346/jkms.2015.30.7.937
- Author:
Eun Ah KIM
1
;
Ye Hwan KIM
;
Ho Won KANG
;
Hyung Yoon YOON
;
Won Tae KIM
;
Yong June KIM
;
Seok Joong YUN
;
Sung Kwon MOON
;
Yung Hyun CHOI
;
Isaac Yi KIM
;
Sang Cheol LEE
;
Wun Jae KIM
Author Information
1. Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. wjkim@chungbuk.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Prostatic Neoplasms;
Gene Expression;
Genes, Tumor Suppressor;
hMOB3B
- MeSH:
Aged;
Aged, 80 and over;
Biomarkers, Tumor/*metabolism;
Case-Control Studies;
Disease Susceptibility;
Gene Expression;
Humans;
Kallikreins/blood;
Male;
Microtubule-Associated Proteins/*metabolism;
Middle Aged;
Neoplasm Grading;
Polymerase Chain Reaction;
Prostate/*pathology/surgery;
Prostate-Specific Antigen/blood;
Prostatic Hyperplasia/blood/pathology;
Prostatic Neoplasms/blood/*pathology/surgery
- From:Journal of Korean Medical Science
2015;30(7):937-942
- CountryRepublic of Korea
- Language:English
-
Abstract:
Mps one binder (MOB) proteins are integral components of signaling pathways that control important cellular processes, such as mitotic exit, centrosome duplication, apoptosis, and cell proliferation. However, the biochemical and cellular functions of the human MOB (hMOB) protein family remain largely unknown. The present study investigated the association between hMOB3B expression and clinicopathological characteristics of prostate cancer (PCa).Study subjects included 137 PCa patients and 137 age-matched benign prostatic hyperplasia (BPH) patients. hMOB3B expression was estimated using real-time PCR and compared with clinicopathological parameters of PCa. hMOB3B mRNA expression was significantly lower in PCa tissues than in BPH control tissues (P<0.001). According to receiver operating characteristics curve analysis, the sensitivity of hMOB3B expression for PCa diagnosis was 84.7%, with a specificity of 86% (AUC=0.910; 95% CI=0.869-0.941; P<0.001). hMOB3B expression was significantly lower in patients with elevated prostate specific antigen (PSA) levels (> or =10 ng/mL), a Gleason score> or =8, and metastatic disease (any T, N+/M+) than in those with low PSA levels, a low Gleason score, and non-metastatic disease (each P<0.05). In conclusion, low levels of hMOB3B are closely associated with aggressive clinicopathologic features in patients with PCa. Our results suggest that hMOB3B may act as a tumor suppressor in human PCa.
